Clinical Trial Detail

NCT ID NCT03111732
Title Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

ampulla of Vater carcinoma

biliary tract cancer


Capecitabine + Oxaliplatin + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.